Literature DB >> 9989717

Tumour necrosis factor alpha and interleukin 1beta in relapse of Crohn's disease.

S Schreiber1, S Nikolaus, J Hampe, J Hämling, I Koop, B Groessner, H Lochs, A Raedler.   

Abstract

BACKGROUND: Concentrations of proinflammatory cytokines are increased in the intestinal mucosa of patients with active Crohn's disease. Experimental immunotherapeutic interventions with anticytokine agents in refractory Crohn's disease show that tumour necrosis factor alpha (TNF alpha) may be an important mediator of inflammation. We investigated the relation between production of TNF alpha and interleukin 1beta by mononuclear cells of the colonic lamina propria in patients with remitting Crohn's disease and the risk of relapse.
METHODS: We followed up 137 patients with Crohn's disease in steroid-induced remission for 1 year. Secretion of proinflammatory cytokines (tumour necrosis factor alpha [TNF alpha] and interleukin 1beta) was assessed after short-term culture of human lamina propria mononuclear cells.
FINDINGS: Increased secretion of TNF alpha and interleukin 1beta were predictive for acute relapses within the next year. Site and extent of disease, baseline demographics, and serum acute-phase proteins had little predictive value.
INTERPRETATION: TNF alpha is important as a target molecule for immune interventions in Crohn's disease. The capacity to produce TNF alpha or interleukin 1beta may identify patients who would benefit from anti-inflammatory remission maintenance.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9989717     DOI: 10.1016/S0140-6736(98)03339-X

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  62 in total

1.  Histopathological parameters as predictors for the course of Crohn's disease.

Authors:  Frauke Bataille; Frank Klebl; Petra Rümmele; Rainer H Straub; Peter Wild; Jürgen Schölmerich; Ferdinand Hofstädter
Journal:  Virchows Arch       Date:  2003-07-24       Impact factor: 4.064

Review 2.  Evaluation of new therapies for inflammatory bowel disease.

Authors:  E Carty; D S Rampton
Journal:  Br J Clin Pharmacol       Date:  2003-10       Impact factor: 4.335

Review 3.  The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review.

Authors:  H Hanai; Y Takeda; M Eberhardson; R Gruber; A R Saniabadi; O Winqvist; R Lofberg
Journal:  Clin Exp Immunol       Date:  2010-11-16       Impact factor: 4.330

Review 4.  Predicting relapse in patients with inflammatory bowel disease: what is the role of biomarkers?

Authors:  D S Pardi; W J Sandborn
Journal:  Gut       Date:  2005-03       Impact factor: 23.059

5.  Rectal nitric oxide as biomarker in the treatment of inflammatory bowel disease: responders versus nonresponders.

Authors:  Tryggve Ljung; Sofie Lundberg; Mark Varsanyi; Catharina Johansson; Peter T Schmidt; Max Herulf; Jon O Lundberg; Per M Hellstrom
Journal:  World J Gastroenterol       Date:  2006-06-07       Impact factor: 5.742

6.  Pit patterns in rectal mucosa assessed by magnifying colonoscope are predictive of relapse in patients with quiescent ulcerative colitis.

Authors:  Y Nishio; T Ando; O Maeda; K Ishiguro; O Watanabe; N Ohmiya; Y Niwa; K Kusugami; H Goto
Journal:  Gut       Date:  2006-05-08       Impact factor: 23.059

Review 7.  Predicting, treating and preventing postoperative recurrence of Crohn's disease: the state of the field.

Authors:  Anna M Borowiec; Richard N Fedorak
Journal:  Can J Gastroenterol       Date:  2011-03       Impact factor: 3.522

8.  Activation of signal transducer and activator of transcription (STAT) 1 in human chronic inflammatory bowel disease.

Authors:  S Schreiber; P Rosenstiel; J Hampe; S Nikolaus; B Groessner; A Schottelius; T Kühbacher; J Hämling; U R Fölsch; D Seegert
Journal:  Gut       Date:  2002-09       Impact factor: 23.059

9.  Ameliorative effect of IDS 30, a stinging nettle leaf extract, on chronic colitis.

Authors:  Astrid Konrad; Michael Mähler; Stephan Arni; Beatrice Flogerzi; Sonja Klingelhöfer; Frank Seibold
Journal:  Int J Colorectal Dis       Date:  2004-08-25       Impact factor: 2.571

10.  Elevated vasoactive intestinal peptide concentrations in patients with irritable bowel syndrome.

Authors:  Olafur S Palsson; Olivier Morteau; Eugene M Bozymski; John T Woosley; R Balfour Sartor; Michael J Davies; David A Johnson; Marsha J Turner; William E Whitehead
Journal:  Dig Dis Sci       Date:  2004-08       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.